Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management
Biotricity (OTCQB:BTCY) has significantly expanded its intellectual property portfolio with 14 new patents, bringing its total to 15 issued patents and 14 pending. The company's latest innovations focus on a breakthrough multi-biometric device platform that can function as both a patch and watch for remote patient monitoring.
The new technology enables simultaneous diagnostic studies through a versatile device with base components that can be transferred between patch and watch form factors. This advancement allows for concurrent diagnostic assessments, such as cardiac and sleep studies, streamlining the patient care process and reducing diagnosis delays.
The expanded patent portfolio reinforces Biotricity's position in remote monitoring, diagnostics, and chronic disease management solutions. The company's Technology-as-a-Service (TaaS) approach aims to improve patient outcomes by enabling earlier detection of health issues while generating revenue through insurance reimbursement.
Biotricity (OTCQB:BTCY) ha ampliato significativamente il suo portafoglio di proprietà intellettuale con 14 nuovi brevetti, portando il totale a 15 brevetti rilasciati e 14 in attesa. Le ultime innovazioni dell'azienda si concentrano su una piattaforma di dispositivi multi-biometrici rivoluzionaria che può funzionare sia come cerotto che come orologio per il monitoraggio remoto dei pazienti.
La nuova tecnologia consente studi diagnostici simultanei attraverso un dispositivo versatile con componenti di base che possono essere trasferiti tra le forme di cerotto e orologio. Questo progresso consente valutazioni diagnostiche simultanee, come studi cardiaci e del sonno, semplificando il processo di cura del paziente e riducendo i ritardi nella diagnosi.
Il portafoglio di brevetti ampliato rafforza la posizione di Biotricity nel monitoraggio remoto, nella diagnostica e nelle soluzioni per la gestione delle malattie croniche. L'approccio dell'azienda, il Technology-as-a-Service (TaaS), mira a migliorare i risultati per i pazienti consentendo una rilevazione precoce dei problemi di salute, generando nel contempo entrate attraverso il rimborso assicurativo.
Biotricity (OTCQB:BTCY) ha ampliado significativamente su cartera de propiedad intelectual con 14 nuevas patentes, llevando el total a 15 patentes emitidas y 14 en espera. Las últimas innovaciones de la empresa se centran en una plataforma de dispositivos multi-biométricos revolucionaria que puede funcionar tanto como un parche como un reloj para el monitoreo remoto de pacientes.
La nueva tecnología permite estudios diagnósticos simultáneos a través de un dispositivo versátil con componentes básicos que se pueden transferir entre las formas de parche y reloj. Este avance permite evaluaciones diagnósticas concurrentes, como estudios cardíacos y del sueño, agilizando el proceso de atención al paciente y reduciendo los retrasos en el diagnóstico.
La cartera de patentes ampliada refuerza la posición de Biotricity en el monitoreo remoto, la diagnóstica y las soluciones para la gestión de enfermedades crónicas. El enfoque de la empresa, Technology-as-a-Service (TaaS), tiene como objetivo mejorar los resultados de los pacientes al permitir una detección temprana de problemas de salud, generando al mismo tiempo ingresos a través del reembolso de seguros.
Biotricity (OTCQB:BTCY)는 14개의 새로운 특허를 통해 지적 재산 포트폴리오를 크게 확장하여 총 15개의 발급된 특허와 14개의 대기 중인 특허를 보유하게 되었습니다. 회사의 최신 혁신은 원격 환자 모니터링을 위한 패치와 시계로 기능할 수 있는 혁신적인 다중 생체 인식 장치 플랫폼에 중점을 두고 있습니다.
이 새로운 기술은 패치와 시계 형태 간에 전송할 수 있는 기본 구성 요소를 가진 다목적 장치를 통해 동시에 진단 연구를 가능하게 합니다. 이 발전은 심장 및 수면 연구와 같은 동시 진단 평가를 허용하여 환자 치료 프로세스를 간소화하고 진단 지연을 줄입니다.
확대된 특허 포트폴리오는 원격 모니터링, 진단 및 만성 질환 관리 솔루션에서 Biotricity의 입지를 강화합니다. 회사의 Technology-as-a-Service (TaaS) 접근 방식은 건강 문제의 조기 발견을 가능하게 하여 환자 결과를 개선하고 보험 환급을 통해 수익을 창출하는 것을 목표로 합니다.
Biotricity (OTCQB:BTCY) a considérablement élargi son portefeuille de propriété intellectuelle avec 14 nouveaux brevets, portant le total à 15 brevets délivrés et 14 en attente. Les dernières innovations de l'entreprise se concentrent sur une plateforme de dispositifs multi-biométriques révolutionnaires pouvant fonctionner à la fois comme un patch et une montre pour la surveillance à distance des patients.
La nouvelle technologie permet des études diagnostiques simultanées grâce à un dispositif polyvalent dont les composants de base peuvent être transférés entre les formes de patch et de montre. Cette avancée permet des évaluations diagnostiques simultanées, telles que des études cardiaques et du sommeil, rationalisant le processus de soins aux patients et réduisant les délais de diagnostic.
Le portefeuille de brevets élargi renforce la position de Biotricity dans la surveillance à distance, le diagnostic et les solutions de gestion des maladies chroniques. L'approche Technology-as-a-Service (TaaS) de l'entreprise vise à améliorer les résultats des patients en permettant une détection précoce des problèmes de santé tout en générant des revenus grâce au remboursement des assurances.
Biotricity (OTCQB:BTCY) hat sein Portfolio an geistigem Eigentum erheblich erweitert und 14 neue Patente hinzugefügt, womit die Gesamtzahl auf 15 erteilte Patente und 14 anhängige Patente steigt. Die neuesten Innovationen des Unternehmens konzentrieren sich auf eine bahnbrechende Plattform für multifunktionale biometrische Geräte, die sowohl als Pflaster als auch als Uhr für die Fernüberwachung von Patienten fungieren kann.
Die neue Technologie ermöglicht gleichzeitige diagnostische Studien durch ein vielseitiges Gerät mit Basiskomponenten, die zwischen Pflaster- und Uhrenformen übertragen werden können. Dieser Fortschritt ermöglicht gleichzeitige diagnostische Bewertungen, wie z. B. Herz- und Schlafstudien, und vereinfacht den Patientenversorgungsprozess, wodurch Diagnoseverzögerungen reduziert werden.
Das erweiterte Patentportfolio stärkt die Position von Biotricity im Bereich der Fernüberwachung, Diagnostik und Lösungen für das Management chronischer Krankheiten. Der Technology-as-a-Service (TaaS)-Ansatz des Unternehmens zielt darauf ab, die Ergebnisse für Patienten zu verbessern, indem eine frühzeitige Erkennung von Gesundheitsproblemen ermöglicht wird und gleichzeitig Einnahmen durch Versicherungsvergütung generiert werden.
- Significant IP portfolio expansion with 14 new patents, strengthening market position
- Innovative multi-biometric platform enables concurrent diagnostic studies, potentially increasing revenue streams
- Technology allows for insurance reimbursement, supporting revenue generation
- Versatile device design supports multiple form factors, expanding potential market applications
- Trading on OTCQB market rather than major exchange
- Heavy reliance on pending patents (14) for future growth
- Dependent on insurance reimbursement approval for revenue generation
Biotricity’s latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care.
REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), (“Biotricity” or the “Company”), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company’s total to 15 issued patents, with an additional 14 patents pending. The expansion of the company’s IP portfolio underscores Biotricity’s commitment to advancing and improving the patient journey. By streamlining diagnostic processes, Biotricity helps medical providers detect potential health issues earlier, improving patient outcomes while also reducing the burden on the stressed healthcare system.
Biotricity’s newest group of patents represents a breakthrough in remote patient monitoring technology, with a focus on multi-sensor patch devices capable of collecting various biometrics. These innovations are centered on a versatile device platform with base components that can be inserted into a patch form factor, then removed and placed into a watch form factor. This adaptable design ensures wider integration and compliance for different patient needs and clinical applications.
This group of patents will drive Biotricity’s next-generation device which could enable multiple diagnostic studies to be conducted simultaneously. For instance, patients needing a cardiac and sleep study would traditionally have to navigate fragmented care pathways, schedule multiple appointments, and endure long wait times. With Biotricity, these critical diagnostic assessments could be performed concurrently with the same device, reducing delays in diagnosis and expediting treatment.
“At Biotricity, we believe that the future of patient care lies in the ability to monitor and manage individuals from the comfort of their home.” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Our solutions deliver actionable data to healthcare providers, facilitating quicker intervention to improve patient outcomes while driving revenue through insurance reimbursement.”
“As part of our R&D strategy, we continue to mindfully develop a robust, diversified IP portfolio that integrates patents, trade secrets, FDA clearances, and trademarks, while ensuring each product or technology is aligned with reimbursement and clinical outcomes. We expect to secure further patents this year and next. By expanding our IP portfolio, we are not only reinforcing our leadership in the industry but also ensuring that our technology remains at the forefront of innovation.”
For more information Biotricity and its state-of-the art suite of remote patient monitoring solutions, please visit www.biotricity.com or contact investors@biotricity.com.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor relations:
Biotricity Investor Relations
Investors@biotricity.com
FAQ
What are the key features of Biotricity's (BTCY) new patent-protected device platform?
How many patents does Biotricity (BTCY) now hold after the March 2025 announcement?
How does Biotricity's (BTCY) new technology improve the patient diagnostic process?
What is the revenue model for Biotricity's (BTCY) remote monitoring solutions?
